Bloomberg Intelligence Podcast
Episode: Alphabet, Amazon Outpace Meta in AI During Earnings Bonanza
Date: April 30, 2026
Hosts: Paul Sweeney, Scarlet Fu
Guests: Mandeep Singh, Anurag Rana, Sam Fazelli, Chris Chilino
Episode Overview
This episode unpacks the latest earnings bonanza among major tech (Alphabet, Amazon, Microsoft, Meta), pharma (Eli Lilly, Merck), and industrial (Caterpillar) players. The focus is on how investments in AI are transforming technology giants, the competitive dynamics of cloud and AI spending, standout trends in pharma with obesity medications, and Caterpillar’s record results as AI infrastructure demand surges. The analysts dig into the numbers, management commentary, and what it all means for investors, with notable moments and direct quotes illuminating the shifting investment landscape.
Key Discussion Points & Insights
1. Big Tech Earnings: AI’s Winners and Losers
Meta Stumbles Despite Growth
- Meta shares dropped 10% due to investor concerns over sharply rising capex (mainly for memory components), with unclear AI monetization timelines.
- Mandeep Singh (02:13):
"Capex increase tied to memory components, not really tied to additional capacity, but it was enough to cause this, you know, 10% drawdown in the stock overall fundamentals were still strong when they reported the quarter for their core business."
- Meta’s AI initiatives are less focused on coding agents (the current growth engine in AI) and more on long-term “personal super intelligence” assistants, but monetization is still vague.
- Paul Sweeney (03:26): Highlights investor skittishness at Meta’s “not very precise plan for how each product will be cultivated.”
Alphabet Shines with Efficiency
- Alphabet raised capex, but by a smaller margin than Microsoft and Meta, reflecting superior capex efficiency.
- Mandeep Singh (03:52):
"Out of all the hyperscalers, [Alphabet] has the best capex efficiency... the cloud business is growing at the fastest rate compared to other hyperscalers."
- Alphabet’s ability to leverage compute across businesses (Search, YouTube, Cloud) fuels margin upside, leading to a robust stock reaction to their earnings beat.
The AI Investment Super Cycle
- Companies are locked into a “super cycle” of AI investment, with demand outpacing supply, particularly in cloud infrastructure.
- Mandeep Singh (05:05):
"When you think about even Amazon $150 billion business growing at 28% and Google $80 billion cloud business growing at 63%. So you are seeing that ROI with these AI investments and there's no reason to curtail that investment when you're seeing this kind of a top line lift."
2. Cloud Race: Microsoft, Amazon, Google Compared
Microsoft
- Azure’s cloud business is now estimated at ~$110 billion, growing at 40%, but its growth was overshadowed by Google’s acceleration.
- Anurag Rana (08:56):
"For Microsoft, growth accelerated 1 percentage point from 38% to 39% in constant currency. But when you look at Google, it went from 48% to 63%. So it's a relative game."
- Microsoft remains an AI leader, especially with Copilot, but user penetration of paid Copilot is still relatively low.
- Anurag Rana (10:35):
"They have about 400 plus million users... only 20 million are paying right now. So the penetration rate is, let's say, about 10%."
Amazon
- AWS at a $150+ billion run-rate, grew 28%. The addition of OpenAI models could further accelerate growth, as the bulk of Fortune 2000 data sits with AWS.
- Anurag Rana (11:53):
"Amazon web services over $150 billion run rate business grew 28%. We think that rate of growth actually improves... They added OpenAI models into their ecosystem ... that’s going to spur even more enterprise AI adoption."
- AWS is well-positioned as enterprises transition from legacy systems to AI-driven "agentic" architectures.
3. Pharma Earnings: Obesity Medications in Focus
Eli Lilly
- Major beat on sales/profits due to international demand for obesity drugs, not just US demand.
- Sam Fazelli (16:18):
"What's driven this $2 billion increase ... is ex-US sales. So that's actually quite good because a lot of people always just keep thinking that everything is all US based."
- Stock popped 9% on the news. Bears had focused too much on the new oral drug’s US rollout and missed the strength in the existing portfolio.
Merck
- Reported a solid but less impressive beat; demand for newer drugs and inventory build were the main drivers.
- Merck is developing (but hasn’t yet launched) a competitive weight loss medication — a space dominated by Lilly and Novo Nordisk.
Market Dynamics: Oral Obesity Drugs
- Eli Lilly’s oral weight loss pill is off to a fast US launch but may face challenges vs. Novo’s more efficacious pill, which must be taken under stricter conditions (e.g., fasting).
- Sam Fazelli (19:03):
"Maybe it's a bit more likely that people will continue on that and that Lily will have a tough time gaining momentum with its oral pill... They have the better obesity injection today in terms of efficacy. Novo has the better pill."
- Both companies are vying for dominance in a market expected to reach $20B+ by 2030.
4. Industrial: Caterpillar’s AI-Related Boom
Caterpillar’s Results
- Caterpillar delivered another top- and bottom-line beat, with all business segments contributing and a record backlog increasing visibility.
- Chris Chilino (23:43):
"Cat continues to deliver against pretty lofty expectations with another top and bottom line beat this quarter...record backlog continues to grow significantly quarter over quarter."
- Raised long-term growth targets, citing especially strong power generation and energy demand.
AI Infrastructure Tailwinds
- Surge in data center construction (to power AI) boosts demand for Caterpillar’s power and energy products.
- Chris Chilino (24:41):
"Not only do we have all these secular tailwinds on the power generation side, but now we're starting to see the cyclical tailwinds start to kick in in terms of construction and mining."
- Growing power backlog helps mitigate business cyclicality, but Caterpillar remains fundamentally a cyclical company.
Caterpillar Stock Milestones
- Shares up 8.8% on the day, 53% YTD, and a massive 184% on a trailing twelve-month basis.
- Paul Sweeney (25:15):
"Wow...52 week high. An all time high for the stock. $880 a share. They need a 10 for 1 split badly. I think so."
Competition
- Major competitors: Komatsu (mining), Deere (construction expansion), Hitachi, Volvo, Cummins (power generation).
Notable Quotes & Memorable Moments
- Mandeep Singh (02:13):
"Capex increase tied to memory components, not really tied to additional capacity, but it was enough to cause this...10% drawdown in the stock."
- Mandeep Singh (03:52):
"Alphabet, out of all the hyperscalers, has the best capex efficiency."
- Anurag Rana (10:35):
"The biggest growth opportunity for [Microsoft]...only 20 million [out of 400M Office users] are paying [for Copilot] right now."
- Sam Fazelli (16:18):
"There's an enormous juggernaut of a business behind [Lilly's new oral pill]...driven by ex-US sales."
- Chris Chilino (23:43):
"[Caterpillar's] record backlog continues to grow significantly quarter over quarter and management raised their long term 2030 growth targets."
Timestamps for Key Segments
- [02:13] – Meta: Earnings reaction & AI capex concerns
- [03:52] – Alphabet: Capex discipline & market reaction
- [05:05] – The AI investment “super cycle” explained
- [08:56] – Microsoft: Azure’s status & Copilot penetration
- [11:53] – Amazon: AWS growth, OpenAI integration & enterprise momentum
- [16:18] – Pharma: Eli Lilly’s obesity drug-driven beat
- [17:31] – Merck: Results & obesity drug pipeline
- [19:03] – Obesity medication market competition
- [23:43] – Caterpillar: Strong quarter & AI infrastructure demand
Conclusion
The episode threads together broad themes of AI-driven investment across tech and industrials, rising differentiation among cloud giants, innovation-led reshuffling in pharma (notably obesity drugs), and the hardware backbone (exemplified by Caterpillar) necessary to sustain the AI boom. Analysts expect the AI supercycle to power capex and revenue growth for years, with investors hunting for clear modernization and ROI signals in company disclosures.
For further insights and full analysis, tune in to Bloomberg Intelligence LIVE weekdays from 10AM to 12PM ET, or catch podcast replays on your preferred platform.